Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet Lond Engl. 28 juill, vol.380, issue.9839, pp.358-65, 2012. ,
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, issue.26, pp.2507-2523, 2011. ,
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib ,
,
,
The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial, Genet Med Off J Am Coll Med Genet. 1 de?, 2016. ,
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discov. juin, vol.7, issue.6, pp.586-95, 2017. ,
,
, Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre
, Lancet Oncol. mars, vol.15, issue.3, pp.267-74, 2014.
Treatment Algorithms Based on Tumor Molecular ProHiling: The Essence of Precision Medicine Trials, J Natl Cancer Inst. avr, vol.108, issue.4, 2016. ,
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis, JAMA Oncol. 6 juin, 2016. ,
Key Lessons Learned from MofHitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience, The Oncologist. fevr, vol.22, issue.2, pp.144-51, 2017. ,
Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer, Oncotarget. 26 mars, vol.7, issue.17, pp.24860-70, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01440517
Implementation and utilization of the molecular tumor board to guide precision medicine, Oncotarget. 22 aou?t, vol.8, issue.34, pp.57845-54, 2017. ,
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response, JAMA Oncol. juill, vol.1, issue.4, pp.466-74, 2015. ,
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Cold Spring Harb Mol Case Stud, vol.1, p.570, 2015. ,
,
, Breast Cancer Experience of the Molecular Tumor Board at the University of California, J Oncol Pract, vol.11, issue.6, pp.442-451, 2015.
Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center, Pediatr Blood Cancer, vol.63, issue.8, pp.1368-74, 2016. ,
, Phase II study of intravenous vinHlunine after failure of Hirst-line vinorelbine based regimen for advanced breast cancer, Breast Edinb Scotl. fevr, vol.22, issue.1, pp.58-63, 2013.
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer. ESMO Open, vol.3, p.28, 2018. ,
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival, N Engl J Med, vol.367, issue.17, pp.1596-606, 2012. ,
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or ampliHication, J Clin Oncol Off J Am Soc Clin Oncol. 20 juill, vol.29, issue.21, pp.2904-2913, 2011. ,
KIT as a therapeutic target in metastatic melanoma, JAMA. 8 juin, vol.305, issue.22, pp.2327-2361, 2011. ,
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer, Lung Cancer Amst Neth. de?, vol.114, pp.96-102, 2017. ,
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors, Cancer Discov. mai, vol.2, issue.5, pp.414-438, 2012. ,
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF, Cancer Res. 1 sept, vol.74, issue.17, pp.4845-52, 2014. ,
Exome sequencing identiHies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma, Nat Genet. 25 de?, vol.44, issue.2, pp.133-142, 2011. ,
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center, The Oncologist. sept, vol.20, issue.9, pp.1011-1019, 2015. ,
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProHiLER trial, Ann Oncol Off J Eur Soc Med Oncol. 13 mars, 2019. ,
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting, JAMA, vol.320, issue.5, pp.469-77, 2018. ,
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden ,
, Genome Med, vol.19, issue.1, p.34, 2017.
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med. juin, vol.23, issue.6, pp.703-716, 2017. ,
Monitoring immune-checkpoint blockade: response evaluation and biomarker development, Nat Rev Clin Oncol, vol.14, issue.11, pp.655-68, 2017. ,
Tumor Mutational Burden and Response Rate to PD-1 Inhibition, N Engl J Med, vol.21, issue.25, pp.2500-2501, 2017. ,
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.350, issue.6257, pp.207-218, 2015. ,
, Mismatch repair deHiciency predicts response of solid tumors to PD-1 blockade, 2018.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science. 3 avr, vol.348, issue.6230, pp.124-132, 2015. ,